greenovation Biotech GmbH welcomes Andreas Hartmann, Ph.D. as the new Chief Business Officer.

Prior to joining greenovation Dr. Hartmann established and managed the German operations for Therabel and Emergent BioSolutions and held local as well as international management,  business development and marketing & sales positions at Emergent BioSolutions, Bavarian Nordic, Ares Serono, Sanofi-Winthrop and Janssen-Cilag.

With greenovation having passed the strategic turning point from an expression platform developer and service provider towards developing customized protein biopharmaceuticals, Dr. Hartmann will intensify the company's international efforts in establishing developmental collaborations and out-licensing/partnering of its advanced lead candidates and selected programs.

greenovation's proprietary Physcomitrella-based BryoTechnology^TM-platform is suitable for expressing complex multi-purpose proteins. In line with streamlining the business focus the BryoTechnology^TM-platform has now preferentially been dedicated to development and production of demanding proteins for pharmaceutical use.

The company's lead candidates, targeting unmet medical needs in orphan indications, are spearheaded by recombinant moss Alpha-Galactosidase, to be developed as enzyme-replacement Therapy (ERT) for patients with Fabry Disease. The pre-clinical development of moss Alpha-Galactosidase is close to being completed. With GMP-manufacturing and protein analytics having been fully established greenovation is confident to move this first ever moss-expressed biopharmaceutical candidate into clinical development in autumn 2014.

“We are pleased to welcome Dr. Hartmann to join greenovation's management team. His appointment underlines the company's recent clear cut specialization in biopharmaceuticals. Dr. Hartmann's extensive executive and hands-on operational knowledge and experience in international (bio)pharmaceutical industry makes him ideally qualified to help further developing and achieving greenovation's business goals and future progress", said Günter Steffen, Chairman of greenovation's Advisory Board.

About greenovation Biotech GmbH

greenovation Biotech GmbH is a specialty biopharmaceutical company developing customized protein biopharmaceuticals using its proprietary eukaryotic Physcomitrella-based BryoTechnology^TM-platform.  

Stable moss lines are developed for a sustainable, cGMP-compliant manufacturing of protein biopharmaceutical candidates. Key features of BryoTechnology^TM: photoautotrophic process: easy to cultivate in animal-derived-component-free and antibiotic-free purely mineral media ? rapid genome customization to express demanding proteins ? genetically stable genomic integration ? eukaryotic post-translational modifications; straightforward genetic glyco-engineering ? highly homogeneous glycosylation pattern ? targeted elimination of plant-type glyco-forms ? protein excretion into the media.

Large scale production using the photoautotrophic moss lines is performed in certified, disposable bag-based reactors of the wave-type. Supply as well as full physico-chemical and biological characterization of GMP material for clinical has been established at greenovation's specialized partner companies.

greenovation has two pre-clinical programs under development, in the area of orphan lysosomal storage diseases (LSD): Moss Alpha-Galactosidase for treating patients with Fabry Disease and Moss Glucocerebrosidase for treating patients suffering from Gaucher's Disease. With the Moss Alpha-Galactosidase program greenovation plans entering into a clinical phase I/IIa trial in the second half of 2014.

more about greenovation